Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2010 1
2013 1
2014 3
2016 1
2018 2
2019 1
2020 5
2021 5
2022 3
2023 10
2024 4
2025 6
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial.
Kurzeder C, Nguyen-Sträuli BD, Krol I, Ring A, Castro-Giner F, Nüesch M, Asawa S, Zhang YW, Budinjas S, Gvozdenovic A, Vogel M, Kohler A, Grašič Kuhar C, Schwab FD, Heinzelmann-Schwarz V, Weber WP, Rochlitz C, Vorburger D, Frauchiger-Heuer H, Witzel I, Wicki A, Kuster GM, Vetter M, Aceto N. Kurzeder C, et al. Among authors: grasic kuhar c. Nat Med. 2025 Apr;31(4):1120-1124. doi: 10.1038/s41591-024-03486-6. Epub 2025 Jan 24. Nat Med. 2025. PMID: 39856336 Free PMC article. Clinical Trial.
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L. Serafini MS, et al. Among authors: kuhar cg. J Immunother Cancer. 2024 Jan 30;12(1):e007823. doi: 10.1136/jitc-2023-007823. J Immunother Cancer. 2024. PMID: 38290766 Free PMC article. Clinical Trial.
The biology and clinical potential of circulating tumor cells.
Lozar T, Gersak K, Cemazar M, Kuhar CG, Jesenko T. Lozar T, et al. Among authors: kuhar cg. Radiol Oncol. 2024 Sep 15;58(3):458. doi: 10.2478/raon-2024-0055. eCollection 2024 Sep 1. Radiol Oncol. 2024. PMID: 39287172 Free PMC article. No abstract available.
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth.
Kamposioras K, Mauri D, Papadimitriou K, Anthoney A, Hindi N, Petricevic B, Dambrosio M, Valachis A, Kountourakis P, Kopecky J, Kuhar CG, Popovic L, Chilingirova NP, Zarkavelis G, de Mello RA, Plavetić ND, Christopoulos C, Mostert B, Goffin JR, Tzachanis D, Saraireh HH, Ma F, Pavese I, Tolia M. Kamposioras K, et al. Among authors: kuhar cg. Front Oncol. 2020 Nov 19;10:575148. doi: 10.3389/fonc.2020.575148. eCollection 2020. Front Oncol. 2020. PMID: 33330049 Free PMC article. Review.
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
Mauri D, Kamposioras K, Matthaios D, Tolia M, Nixon I, Dambrosio M, Zarkavelis G, Papadimitriou K, Petricevic B, Kountourakis P, Kopecky J, Grašič Kuhar C, Popovic L, Chilingirova NP, De Mello RA, Dedić Plavetić N, Katsanos K, Mostert B, Alongi F, de Bari B, Corradini S, Kampletsas E, Gazouli I, Gkoura S, Amylidi AL, Valachis A. Mauri D, et al. Among authors: grasic kuhar c. Oncol Res Treat. 2022;45(4):216-221. doi: 10.1159/000521845. Epub 2022 Jan 9. Oncol Res Treat. 2022. PMID: 34999585 Free article. Review.
43 results